TY - JOUR
T1 - Ondansetron Use During Pregnancy
T2 - Birth Defects and Obstetric Outcomes
AU - Masarwe, Sabaa
AU - Shvartsur, Rachel
AU - Hadar, Eran
AU - Betesh-Abay, Batya
AU - Peleg, Noam
AU - Azab, Abed N.
N1 - Publisher Copyright:
© The Author(s) 2023.
PY - 2023/5/1
Y1 - 2023/5/1
N2 - Ondansetron is a widely administered medication for nausea and vomiting of pregnancy. Further examination of its teratogenic capacity is necessary. This study examines the association between ondansetron treatment during pregnancy and birth defects and adverse obstetric outcomes. Patient data were extracted from Clalit Health Services, Israel. A propensity-score analysis was performed matching those exposed to ondansetron with those who were not. Findings identified 774 women exposed to ondansetron, matched 1:1 with unexposed control patients. No significant differences were found between the groups for: cleft palate, cardiovascular congenital abnormalities, spina bifida occulta, preterm delivery, or small for gestational age. Ondansetron may be a useful and safe alternative as treatment for women who suffer from hyperemesis gravidarum and do not respond to other antiemetic drugs. Notwithstanding, additional prospectively designed research is needed to establish the safety of ondansetron treatment during pregnancy.
AB - Ondansetron is a widely administered medication for nausea and vomiting of pregnancy. Further examination of its teratogenic capacity is necessary. This study examines the association between ondansetron treatment during pregnancy and birth defects and adverse obstetric outcomes. Patient data were extracted from Clalit Health Services, Israel. A propensity-score analysis was performed matching those exposed to ondansetron with those who were not. Findings identified 774 women exposed to ondansetron, matched 1:1 with unexposed control patients. No significant differences were found between the groups for: cleft palate, cardiovascular congenital abnormalities, spina bifida occulta, preterm delivery, or small for gestational age. Ondansetron may be a useful and safe alternative as treatment for women who suffer from hyperemesis gravidarum and do not respond to other antiemetic drugs. Notwithstanding, additional prospectively designed research is needed to establish the safety of ondansetron treatment during pregnancy.
KW - antiemetics
KW - birth defects
KW - congenital heart defects
KW - hyperemesis gravidarum
KW - ondansetron
UR - http://www.scopus.com/inward/record.url?scp=85150690627&partnerID=8YFLogxK
U2 - 10.1177/10547738231159062
DO - 10.1177/10547738231159062
M3 - Article
C2 - 36912091
AN - SCOPUS:85150690627
SN - 1054-7738
VL - 32
SP - 705
EP - 711
JO - Clinical Nursing Research
JF - Clinical Nursing Research
IS - 4
ER -